Abstract. Although increased thyroxine sulfate (T4S) levels have recently been detected in fetal serum and amniotic fluid, changes in patients in a high thyroxine (T4) state remain unclarified. This study was conducted to determine the changes in T4S in thyroid hormone regulation in women receiving suppressive T4 therapy. With a highly sensitive and specific radioimmunoassay, we measured the serum and urinary concentrations of T4S in 16 premenopausal women with benign nodular goiter before and after three months administration of T4 (3.2 µg/kg/day).
EARLIER studies in adult humans and rats have demonstrated the ability to maintain circulating 3,3',5-triiodothyronine (T3) at nearly normal levels with either thyroxine (T4) deficiency or excess [1, 2] , but the homeostatic mechanism in man is different from that found in the rat [3] . The majority of circulating T3 in man appears to be derived from peripheral tissue T4 conversion rather than direct thyroid secretion [2] . In normal conditions, about 80% of total T4 is metabolized by way of monodeiodination into either bioactive T3 or biologically inert 3,3',5'-triiodothyronine (rT3), and the remaining 20% is thought to be metabolized by alternate pathways [4] . Metabolism of thyroid hormone (TH) by alternate pathways is augmented in some pathophysiological situations such as intrauterine life, caloric deprivation, nonthyroidal illnesses (NTIs), in high T4 states in humans and administration of 6-propyl-2-thiouracil (PTU) or iopanoic acid (TOP) in rats and humans [5] [6] [7] [8] [9] .
Thyrosulfoconjugation is one of the major alternate pathways of TH metabolism and is catalyzed by phenol sulfotransferase in the cytosolic fractions of several tissue types of humans and rats, and mainly in the liver [10, 11] . In contrast to HUANG et al. glucuronidated iodothyronines, which mainly contribute to the entero-hepatic circulation of TH, sulfoconjugation participates in human systemic TH metabolism and may play a role in response to physiological requirements [12] . Available data from studies in rats indicate that sulfation of TH results in the inactivation of these hormones and enhancement of their excretion in urine and bile [13] .
A recent observation in a human study has shown that the majority of normal T3 disposal occurs via T3 sulfate (T3S) formation [14] , but little work regarding the effect of a high T4 state on the changes in thyroxine sulfate (T4S) concentrations in biologic fluids of adult humans has been reported. In the present study of 16 patients on suppressive T4 therapy, we measured the serum levels and urinary excretion of T4S by a T4S radioimmunoassay (RIA) [7] . To address the relationship between T4S and other TH, correlation studies were also performed.
Patients

Materials and Methods
A group of 16 premenopausal women aged 28 to 42 (mean 34) years with benign nodular goiter participated in the present study. All of them were euthyroid, with no evidence of renal, hepatic or other endocrinological diseases. All were normally active outpatients and were not taking medication with a known effect on thyroid or renal function. Written instructions for correct urine collection were supplied to all patients.
Urine samples were collected after the first voided morning specimen and blood samples were drawn at the same time.
Patients were then instructed to take T4 (3.2 ± 0.6 jig/kg/day) for 3 months. At the end of the study, while the patients were still taking T4, the same sampling procedure was performed. All patients gave their informed consent as part of a protocol approved by the Ethics Committee of the Hospital.
All serum and urine specimens were stored at -70 °C until the completion of the study and then analyzed at the same time for concentrations of various TH parameters. T4S RIA T4S, both radiolabeled and unlabeled, was prepared by the method described by EelkmanRooda and coworkers [15] . The RIA employed an anti-L-TS antibody (Wu091) obtained from rabbits immunized with L-T4S-bovine serum albumin conjugate [7] . In a final dilution of 1:20,000, anti-T4S antibody bound to about 40% of a trace amount (5 pg) of [I-125]-T4S in 0.075 M barbital buffer (pH 8.6) containing 0.1% sodium azide and 0.125% normal rabbit serum. Ethanol did not inhibit the binding of [I-125]-T4S to the antibody up to a final concentration of 22%. We therefore employed ethanol (63%) extracts of sera and urine to measure T4S concentrations. The final ethanol concentration in the assay was 19%.
The T4S RIA was modified for measurement of serum and urine ethanol extracts, as described previously [7] . Briefly, it was carried out in duplicate in 10 x 75 mm glass tubes. RIA tubes contained 0.053 M barbital buffer (pH 8.6), 0.07% sodium azide, 0.088% normal rabbit serum, 19% ethanol and either an unknown or a standard amount of unlabeled T4S (1 to 1000 pg), diluted antiserum, and approximately 10,000 cpm [I-125]-T4S in a final volume of 1 mL. The tubes were thoroughly mixed and incubated at 4°C overnight. A sufficient amount of the titered second antibody was then added. The tubes were mixed, incubated at 4°C overnight, and centrifuged at 2,000 x g for 20 min. Supernatants were aspirated, and the radioactivity in the precipitates was quantified in an LKB 1272 Clinigamma counter (Wallac, Turku, Finland). Nonspecific binding (determined in tubes without added antiserum) was < 5% and was corrected for. Standard curve plots, and other calculations were carried out by means of pre-set programs in the v-counter. The lower limit of detection for T4S was 2 ng/dL in a 300 µL ethanol extract. Cross-reactivities were, T4, < 0.002%; rT3r Serum T3, T4, rT3 and FT4 levels pre-and posttreatment are given in Table  1 . Serum T3 concentrations did not change significantly after treatment (134 ± 11 vs. 115 ± 6 ng/dL).
The mean serum T4 and FT4 concentrations were significantly higher post-treatment although both were still within normal limits (11.1 ± 1.3 vs. 6.6 ± 1.6 ,ug/dL, P<0.01 and 2.1 ± 0.2 vs. 1.2 ± 0.1 ng/dL, P<0.01 respectively).
The TSH values were significantly lower post-treatment (0.12 ± 0.02 vs. 0.69 ± 0.17 mU / L, P<0.01) and were below the normal range. In view of the serum TH changes, subclinical or tissue hyperthyroidism was strongly suspected.
T4S concentrations in serum and urine
No significant concentrations was increase in serum found after treatment.
T4S
In Table 1 . Changes in thyroid hormone levels before and after thyroxine therapy in premenopausal women with nodular goiter contrast to serum levels, relatively large amounts of T4S existed in urine. The urinary levels of T4S were also significantly increased after treatment (20 ± 3.1 vs. 12 ± 1.4 ng/dL or 396 ±46 vs. 174±36 ng/g creatinine, P<0.01 respectively) ( Table 2 ).
Correlation o f urinary T4S and serum thyroid hormones Table 3 shows the correlations of urinary T4S values and the corresponding serum levels of TSH, T4, and FT4. The closest correlation was found between urinary T4S levels and serum FT4 (r=0.64, P<0.01) (Fig. 1) .
Discussion
In the present study, we observed a significant increase in urinary excretion of T4S in patients after T4 treatment, although only low T4S values were detectable in serum both pre-and post-T4 treatment.
We also demonstrated a close correlation between urinary T4S and the corresponding serum T4, FT4
and TSH values. The correlation between creatinine corrected urine TS and serum FT4 values were the most consistent. Our data suggest that substrate availability may play an important role in the changes in urinary T4S. These results are consistent with our earlier report [7] and that of Nicoloff and LoPresti [9] .
The T4 levels after treatment in the present study were significantly higher than those before treatment.
Moreover, TSH levels after T4 treatment were suppressed below the cut-off values after treatment (0.12 ± 0.02 mU/L; normal range: 0.3-5.0 mU/L), suggesting that the patients were borderline hyperthyroid due to high levels of T4 supplement.
Notably, the mean serum T3 value in patients during treatment remained relatively stable compared to that before treatment (115 vs. 134 ng/dL, P>0.05). This is consistent with the phenomenon of "autoregulation" proposed by Nicoloff and LoPresti to describe the protection of human tissue from exposure to excessive amounts of T3 [9] . In this model, as serum T4 values increase, the efficiency of T4 to T3 conversion decreases [9] , leading to a discrepancy between rates of T4 degradation and the formation of monodeiodinated derivates in patients treated with increasing doses Table 2 . Changes in sulfated thyroxine levels in serum and urine before and after thyroxine therapy in premenopausal women with nodular goiter Table 3 . Correlations between serum thyroid hormone profiles and creatinine corrected urine sulfated 14 (T4Uc) levels Correlation between serum free 14 values (ng/dL) and the corresponding corrected urine T4S levels (ng/g creatinine) before (0) and after (•) thyroxin therapy.
of T4 [16] . A similar result was also reported by Inada et al. [17] .
Available evidence from kinetic studies indicates that metabolism of TH in patients in a high T4 state involves a T4 disposal accounting gap [9] , indicating that some products are made intracelluarly and are degraded or leave cells for disposal elsewhere, without equilibrating with the plasma pool. Our present data, along with earlier studies, show that sulf oconjugation of TH in man may be an important pathway contributing to the accounting gap [7, 9, 14] .
T4S is an intermediate metabolite of TH metabolism, and is formed on the tissue level in response to changes in the T4 concentration, as found in fetal sheep [18] . In a human study, an inverse relationship between the efficiency of conversion of T4 to 13, and the production of sulfated metabolites was also noted [16] . Notably, this regulatory metabolism appears to respond instantly [16, 17] . It is therefore plausible to speculate that the changes in T4S may provide a clue that reflects the optimal 14 level in human tissues.
Although many factors affect the metabolism of thyrosulf oconjugates, activities of tissue phenol sulf otransferase (PSTs), monodeiodinase and thyroid status appear to be the most important determinants [10] [11] [12] 19, 20] .
Sulfation of TH is catalysed by multiple PST isoenzymes in human tissues [10, 11] . Although 14 is not thought to be a good substrate for sulfation in vitro [12] , Sato et al. showed accumulation of T4S in primary cultures of rat hepatocytes, while type I monodeionase (MDI) was inhibited or saturated at a high 14 concentration [21] . In the current study, the subjects were actually in high 14 and relatively hyperthyroid states after treatment. The latter, as observed in rats, was thought to be a cause of decreasing MDI activity and to result in a decreasing rate of TS degradation [22] . These facts imply that accumulation of TS in the urine of 14 treated patients may be due to increased production or decreased catabolism, or both, but owing to increased polarity after sulfation of TH, the T4S that exists in the circulation may be promptly excreted by the kidneys. It is therefore not surprising to have a relatively high level of TS in the urine but a low level in the serum, as found in our present study. Similarly, Rutgers et al. reported there was no detectable change in serum T4S, though an increase occurred in bile in rats receiving intravenous radiolabeled 14, even after PTU treatment [23] . Our results are also consistent with a previous human study showing that the urinary excretion of thyrosulf oconjugates correlates with their daily production [24] . The urinary excretion of sulfated compounds in particular may be affected by tissue 13 levels [20] . To what extent this phenomenon affects patients in high 14 states is not known.
A relatively low 14 to 13 conversion rate is suggested by the lower T3/T4 (molar) ratio of 0.014 post-treatment (vs. 0.020 pre-treatment), indicating that the activity of converting enzyme (MDI) was decreased. This suggests that the increased amount of TS after treatment may have been derived from a higher 14 concentration and lower MDI activity. 145 is rapidly converted to reverse T3 sulfate (rT3S) due to a remarkable decrease in Km and increases in Vmax values in inner ring deiodination, as shown in rats [22] . A significant increase in creatinine corrected urinary rT3S was also observed in our subjects after T4 treatment (647 ± 121 vs. 215 ± 42 ng/g Cr. before treatment; P<0.01) (unpublished data). Although the extent of T4S contribution to the measurement of urinary rT3S is still unknown, increased urinary excretion of T4S and its analogs appears to be an alternative metabolic step in "autoregulation" and may be partialy responsible for the 14 disposal gap in high T4 states. Clearly, more kinetic work on T4S metabolism and excretion is needed to obtain more accurate quantitative data regarding this issue.
In conclusion, the present study serves as a preliminary report to rationalize the relationship between urinary excretion of 145 and serum concentrations of FT4 in T4 treated subjects with relative hyperthyroxinemia, a commonly encountered clinical situation. The study of creatinine-corrected urine concentrations of T4S therefore appears to be a supplementary method for the evaluation of subclinical tissue changes that result from overzealous 14 treatment.
